CSS
SEEL

Cubist Systematic Strategies’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Cubist Systematic Strategies’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6
Closed -$28.8K – 4073
2023
Q2 		$28.8K Buy
+6
New +$20.8K ﹤0.01% 3155
2021
Q4 		– Sell
-46
Closed -$430K – 3680
2021
Q3 		$430K Buy
46
+4
+10% +$34.4K 0.01% 2136
2021
Q2 		$422K Buy
42
+28
+200% +$460K ﹤0.01% 2118
2021
Q1 		$264K Buy
+14
New +$163K ﹤0.01% 2328

Other funds holding SEEL

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Cubist Systematic Strategies's SEEL Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2023, closing a stake of 6 shares — an estimated $28.8K sold.

Cubist Systematic Strategies first reported a position in SEEL in Q1 2021 and held it in 4 quarters. The position peaked at $430K in Q3 2021. 67 funds tracked by Wall St. Rank hold SEEL as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 6 Seelos Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $28.8K.
  • Cubist Systematic Strategies first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Cubist Systematic Strategies's Seelos Therapeutics, Inc. Common Stock position peaked at $430K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.